Thus, future clinical trials should examine the response of adiposity to sclerostin neutralizing antibody treatment with and without exercise training in individuals with obesity and metabolic syndrome to separate the exercise induced responses from those of such treatment in humans. This evidence concerns the gene SOST and obesity disorder.